Jan 26, 2023 04:05PM
Oct 26, 2022 08:30AM
Jul 27, 2022 04:05PM
Jul 27, 2022 04:05PM
Jun 17, 2022 06:46AM
Jun 17, 2022 06:45AM
Jun 17, 2022 06:45AM Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 2, 2022 06:51AM
Jun 2, 2022 06:50AM
Jun 2, 2022 06:50AM
May 10, 2022 06:55AM
May 10, 2022 06:55AM
May 6, 2022 06:45AM
May 6, 2022 06:45AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
May 6, 2022 06:45AM
Dec 10, 2021 10:26AM
Sep 9, 2021 06:59AM
Sep 9, 2021 06:58AM
Sep 9, 2021 06:58AM
Aug 26, 2021 09:00AM
Aug 26, 2021 09:00AM Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
Aug 4, 2021 09:49AM
Aug 4, 2021 09:49AM
Jan 6, 2021 06:03AM
Oct 21, 2020 08:30AM
Oct 21, 2020 08:30AM
Sep 29, 2020 08:33AM
Sep 29, 2020 08:30AM Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep 29, 2020 08:30AM
Sep 14, 2020 08:33AM
Sep 14, 2020 08:30AM
Sep 14, 2020 08:30AM
Aug 17, 2020 08:33AM
Aug 17, 2020 08:30AM
Aug 17, 2020 08:30AM Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Jun 22, 2020 10:14PM
Jun 22, 2020 08:32AM
Jun 22, 2020 08:30AM
Jun 22, 2020 08:30AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All